

The following is a complete listing of all claims in the application, with an indication of the status of each:

Listing of claims:

1-18. (Cancel)

19. (Currently amended) A method for radiosensitizing cancer cells, comprising the step of delivering to said cancer cells an effective dose of an expressible nucleic acid encoding a dominant negative carboxy terminal deletion mutant epidermal growth factor receptor that is dominant negative, wherein said cancer cells are *in vivo*, and wherein the nucleic acid is administered directly to a tumor comprising cancer cells *in situ* at the cancer locus.

20. (Currently amended) The method of claim 19, wherein said dominant negative carboxy terminal deletion mutant epidermal growth factor receptor that is dominant negative is EGFR-CD533.

21. (Original) The method of claim 19 wherein said expressible nucleic acid molecule is a DNA molecule.

22. (Currently amended) The method of claim 19 wherein said expressible nucleic acid molecule is in an expression cassette contained in a recombinant adenovirus.

23. (Currently amended) The method of claim 22 wherein said expression cassette recombinant adenovirus is Ad-EGFR-CD533.

24. (Original) The method of claim 19 wherein said expressible nucleic acid molecule is an RNA molecule.

25. (Original) The method of claim 19 wherein said step of delivering is accomplished by administration to a patient in need thereof.

26-28. (Cancelled)

29. (Original) The method of claim 25 wherein said administration is carried out via a method selected from the group consisting of administering a viral vector, administering liposomes, and direct injection of nucleic acid.

30. (Original) The method of claim 19 wherein said cancer cells are mammary cancer cells.

31. (Original) The method of claim 19 wherein said cancer cells are glioma cells.

32. (Original) The method of claim 19 wherein said cancer cells express epidermal growth factor receptor.

33-35. (Cancelled)